About Bovine Respiratory Disease Treatment
Bovine respiratory disease is a multifactorial and complex disorder caused due to a combination of more than one microbial pathogens, inadequate housing conditions, impaired host immunity, and environmental factors.
Technavio’s analysts forecast the global bovine respiratory disease treatment to grow at a CAGR of 8.11% during the period 2017-2021.
Covered in this report
The report covers the present scenario and the growth prospects of the global bovine respiratory disease treatment for 2017-2021. To calculate the market size, the report considers the include sales of branded drugs, generic drugs, and vaccines.
The market is divided into the following segments based on geography:
• Americas
• APAC
• EMEA
Technavio's report, Global Bovine Respiratory Disease Treatment 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors
• Bayer HealthCare
• Boehringer Ingelheim
• Elanco
• Merck
• Zoetis
Other prominent vendors
• Bimeda Group
• Ceva
• Huvepharma
• Inovio Pharmaceuticals
• Med-Pharmex
• Norbrook Laboratories
• Plumbline Life Sciences
Market driver
• Development of novel products
• For a full, detailed list, view our report
Market challenge
• High cost of therapies coupled with presence of natural alternatives
• For a full, detailed list, view our report
Market trend
• Growing focus on the development of combination drugs
• For a full, detailed list, view our report
Key questions answered in this report
• What will the market size be in 2021 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.
Table of Contents
PART 01: Executive summary
PART 02: Scope of the report
PART 03: Research Methodology
PART 04: Introduction
• Key market highlights
PART 05: An overview of bovine respiratory disease
PART 06: Market landscape
• Market overview
• Five forces analysis
PART 07: Market segmentation by product category
• Antibiotics
• Vaccines
• Others
PART 08: Geographical segmentation
• BRD vaccine market in Americas
• BRD treatment market in EMEA
• BRD treatment market in APAC
PART 09: Decision framework
PART 10: Drivers and challenges
• Market drivers
• Impact of drivers on key customer segments
• Market challenges
• Impact of challenges on key customer segments
PART 11: Market trends
• Growing focus on the development of combination drugs
• Increase in preventive measures
• Advancements in technology
PART 12: Vendor landscape
• Competitive scenario
PART 13: Key vendor analysis
• Bayer HealthCare
• Boehringer Ingelheim
• Elanco
• Merck
• Zoetis
• Other prominent vendors
PART 14: Appendix
• List of abbreviations
List of Exhibits
Exhibit 01: Global BRD treatment market
Exhibit 02: Global BRD treatment market 2016-2021 ($ millions)
Exhibit 03: Opportunity analysis in global BRD treatment market
Exhibit 04: Five forces analysis
Exhibit 05: Market segmentation by product category 2016
Exhibit 06: Important antibiotics prescribed for treatment for BRD
Exhibit 07: Global antibiotics segment in BRD treatment market 2016-2021 ($ millions)
Exhibit 08: Important vaccines for prevention of BRD
Exhibit 09: Global vaccines segment in BRD treatment market 2016-2021 ($ millions)
Exhibit 10: Global others segment in BRD treatment market 2016-2021 ($ millions)
Exhibit 11: Segmentation of global BRD treatment market based on geography 2016 and 2021
Exhibit 12: BRD treatment market revenue by geography 2016-2021 ($ millions)
Exhibit 13: Market scenario in Americas
Exhibit 14: BRD treatment market in Americas 2016-2021 ($ millions)
Exhibit 15: Market scenario in EMEA
Exhibit 16: BRD treatment market in EMEA 2016-2021 ($ millions)
Exhibit 17: Market scenario in APAC
Exhibit 18: BRD treatment market in APAC 2016-2021 ($ millions)
Exhibit 19: Impact of drivers
Exhibit 20: Impact of challenges
Exhibit 21: Competitive structure analysis of global BRD treatment market 2016
Exhibit 22: Competitive analysis of global BRD treatment market
Exhibit 23: Strategic success factors of companies in global BRD treatment market
Exhibit 24: Bayer HealthCare: Key highlights
Exhibit 25: Bayer HealthCare: Strength assessment
Exhibit 26: Bayer HealthCare: Strategy assessment
Exhibit 27: Bayer HealthCare: Opportunity assessment
Exhibit 28: Boehringer Ingelheim: Key highlights
Exhibit 29: Boehringer Ingelheim: Strength assessment
Exhibit 30: Boehringer Ingelheim: Strategy assessment
Exhibit 31: Boehringer Ingelheim: Opportunity assessment
Exhibit 32: Elanco: Key highlights
Exhibit 33: Elanco: Strength assessment
Exhibit 34: Elanco: Strategy assessment
Exhibit 35: Elanco: Opportunity assessment
Exhibit 36: Merck: Key highlights
Exhibit 37: Merck: Strength assessment
Exhibit 38: Merck: Strategy assessment
Exhibit 39: Merck: Opportunity assessment
Exhibit 40: Zoetis: Key highlights
Exhibit 41: Zoetis: Strength assessment
Exhibit 42: Zoetis: Strategy assessment
Exhibit 43: Zoetis: Opportunity assessment
